Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06766071 · ClinicalTrials.gov registry record
IPGx PILOT Whole Genome Sequencing Extension Cohort
A clinical trial of Adverse Drug Reaction (ADR) and Polypharmacy Patients, sponsored by Texas A&M University.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06766071 is a study of Adverse Drug Reaction (ADR) and Polypharmacy Patients that is actively recruiting participants, run by Texas A&M University. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06766071, a study of Adverse Drug Reaction (ADR) and Polypharmacy Patients, is actively recruiting participants, sponsored by Texas A&M University.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice including Whole Genome Sequencing (WGS).
Conditions Studied
Study Locations (1)
Texas
- Texas A&M Family Care - Bryan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-01 |
| Est. Completion | 2026-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06766071
The ClinicalTrials.gov registry entry for NCT06766071 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas A&M University, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adverse Drug Reaction (ADR) appearing as the primary indexed condition, and to 0 interventions.
NCT06766071 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06766071 about?
NCT06766071 is a clinical study titled "IPGx PILOT Whole Genome Sequencing Extension Cohort". The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from th...
What is the current status of trial NCT06766071?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-01. Estimated completion is 2026-01.
What conditions does trial NCT06766071 study?
This clinical trial studies the following conditions: Adverse Drug Reaction (ADR), Polypharmacy Patients.
Who is sponsoring clinical trial NCT06766071?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06766071 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adverse Drug Reaction (ADR)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.